Last reviewed · How we verify
Remifentanil adapted to SPI
Remifentanil is a potent opioid agonist that binds to mu-opioid receptors to provide rapid-onset, short-acting analgesia and sedation, with dosing adapted to Surgical Pleth Index (SPI) for real-time pain monitoring.
Remifentanil is a potent opioid agonist that binds to mu-opioid receptors to provide rapid-onset, short-acting analgesia and sedation, with dosing adapted to Surgical Pleth Index (SPI) for real-time pain monitoring. Used for Intraoperative analgesia and sedation during general anesthesia, guided by Surgical Pleth Index monitoring.
At a glance
| Generic name | Remifentanil adapted to SPI |
|---|---|
| Sponsor | Erasme University Hospital |
| Drug class | Opioid agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Perioperative Pain Management |
| Phase | FDA-approved |
Mechanism of action
Remifentanil activates mu-opioid receptors in the central nervous system to produce analgesia and sedation. The SPI adaptation represents a closed-loop or guided dosing approach where the Surgical Pleth Index—a non-invasive measure of nociception derived from photoplethysmography—is used to titrate remifentanil dosing in real-time during anesthesia, aiming to optimize pain control while minimizing overdosing.
Approved indications
- Intraoperative analgesia and sedation during general anesthesia, guided by Surgical Pleth Index monitoring
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Muscle rigidity
- Nausea and vomiting
Key clinical trials
- Comparison of Pupillometry-guided Anesthesia With Surgical Pleth Index Guided Anesthesia (NA)
- Comparison of Different Analgesia-Monitors in Tracing Unconscious Pain Sensations (NA)
- Effect of Pupilometer Guided Analgesia on Postoperative Pain (NA)
- Monitor-Guided Analgesia During General Anesthesia - Part II (NA)
- Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil adapted to SPI CI brief — competitive landscape report
- Remifentanil adapted to SPI updates RSS · CI watch RSS
- Erasme University Hospital portfolio CI